Innosuisse supports CASE BioMed for the 2022-2024 period


Institutional Communication Service

25 January 2021

Innosuisse has decided to support the Comprehensive Advanced Program on BioBusiness of the Center of Advanced Studies on Entrepreneurship in BioMedicine (CASE BioMed), a structure within USI Faculty of Biomedical Sciences for the period 2022-2024.

Innosuisse's funding for CASE BioMed, granted following an extremely competitive national call, thus joins the support already in place for the new Comprehensive Advanced Programme on eHealth Business, in the period in question.

According to Dr Heidrun Flaadt Cervini, Director of CASE BioMed, "With this support Innosuisse is also actively promoting the eHealth Business and BioBusiness programmes on a national basis. It is an important decision that once again confirms the great significance of the BioBusiness programme in the field of life science start-ups in Switzerland."

Thanks to Innosuisse's essential contribution, CASE BioMed's overall financial situation for 2021-2024 is solid and allows for the continued implementation/continuation of the eHealth Business and BioBusiness programs.


CASE BioMed is a structure of USI Faculty of Biomedical Sciences, the first academic institution in Switzerland to offer a series of leading-edge comprehensive advanced programmes in life sciences since 2010. Its internationally renowned initiatives also include, among others, collaborations with MIT Life Science Angels in Boston and UZH Zurich. A book "Bio- and MedTech Entrepreneurship-From start-up to exit" by Heidrun Flaadt Cervini and Jörg Dogwiler was published in 2018. Its second edition, published by Stämpfli Verlag in 2020 as a BoD and as an ebook, has been sold in 8 countries, including the US. To date, CASE BioMed has trained about 350 young entrepreneurs from across Europe.